HCV NS5A Inhibitor Pseudopolymorphs for Enhanced Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HCV NS5A inhibitors have limitations in effectively inhibiting HCV viral replication and treating HCV infection, particularly in enhancing bioavailability and dissolution behavior.
Innovation Solution
Development of pseudopolymorphs of Compound A, including amorphous forms and solvates, combined with concentration-enhancing polymers and surfactants, using methods like spray drying and hot melt extrusion to create pharmaceutical compositions that enhance bioavailability and dissolution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HCV NS5A inhibitors are used, then viral replication can be inhibited, but bioavailability and dissolution behavior are insufficient
Solution Approach 1:
The patent changes the physical and chemical parameters of Compound A by creating pseudopolymorphic forms (solvates, hydrates, amorphous forms) to improve dissolution behavior and bioavailability while maintaining antiviral activity. Different solvates (Form A-J) with varying solvent molecules alter solubility parameters without changing the core chemical structure.
Solution Approach 2:
The patent creates composite pharmaceutical compositions by combining pseudopolymorphic forms of Compound A with concentration-enhancing polymers and surfactants. This composite approach enhances bioavailability through the synergistic effects of the pseudopolymorph structure and the excipient materials.
2Stability of the object's composition
If crystalline forms of Compound A are used, then stability is improved, but dissolution rate decreases
Solution Approach 1:
The patent creates amorphous forms and solvates of Compound A that alter the physical state and molecular arrangement, enabling faster dissolution rates while maintaining compositional stability through controlled solvation and amorphous structure preservation.
Solution Approach 2:
The patent utilizes phase transitions between crystalline, solvate, and amorphous forms of Compound A to optimize dissolution behavior. By controlling the phase state through solvate formation and amorphization processes, the patent achieves enhanced dissolution rates while maintaining stability through proper formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pseudopolymorphs of Compound A effectively inhibit HCV viral replication and improve treatment outcomes by increasing bioavailability and dissolution, addressing the limitations of existing HCV NS5A inhibitors.
Implementation Method 1
a concentration-enhancing polymer, where the polymer increases the bioavailability or enhances the dissolution behavior of Compound A, and is water soluble or readily disperses in water
Implementation Method 2
optionally one or more surfactants
Data Source
AI summary
The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.